Pharmidex

Mohammad Alavijeh is a science entrepreneur with over 20 years experience in the pharmaceutical industry, having responsibilities as wide-ranging as R&D and innovation, business development and strategic alliances. His experience covers most therapeutic areas, notably CNS, obesity, diabetes, cardiovascular, infection, cancer and inflammation (asthma and arthritis). Dr. Alavijeh is now a world leading authority in CNS DMPK, with distinctive competence in neuro-pharmacokinetics. He also has extensive experience of drug discovery and has made a significant contribution to the development of drugs and drug candidates targeting amyotrophic lateral sclerosis, cancer, obesity and Parkinson's disease. Prior to co-founding Pharmidex in 2003, a company that has grown into a world leader in CNS solutions powered by NeuroPK®, Dr. Alavijeh was head of drug metabolism, pharmacokinetic and pharmacodynamic (DMPK/PD) at Vernalis Research, before which he was DMPK team leader at Aventis Pharma. On the academia front, Dr. Alavijeh worked within the Clinical Neurology Department at the Institute of Neurology, University College London.